Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P42345 (
mTOR
)
26,049
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Immune thrombocytopenia (ITP) is an acquired autoimmune disease characterized by an immune mediated decrease in platelet number. Disturbance of CD4
+
T-cell homeostasis with simultaneous decrease of CD4
+
CD25
+
Foxp3
+
regulatory T cells (Tregs) as well as unrestricted proliferation and activation of peripheral CD4
+
effector T cells underpin the pathophysiology of ITP.
Indirubin
is an active ingredient of a traditional Chinese herb called Indigofera tinctoria L. which is clinically used for the treatment of ITP patients. Whether indirubin targets the Tregs/effector T cell-axis to restore platelet number is unknown. In our in vitro studies,
Indirubin
could significantly enhance the number and function of Tregs and meanwhile dampen the activation of effector T cells in a dose-dependent manner.
Indirubin
was observed to restore the expression of programmed cell-death 1 (PD1) and phosphatase and tensin homolog (PTEN) on the CD4
+
T cells of ITP patients, leading to the subsequent attenuation of the AKT/
mTOR
pathway. Furthermore, these observations were recapitulated in an active murine model of ITP with a prominent platelet response. Thus, our results identified a potentially novel mechanism of the therapeutic action of indirubin in the treatment of ITP through regulating the homeostasis of CD4
+
T cells in a PD1/PTEN/AKT signalling pathway.
...
PMID:Indirubin modulates CD4
+
T-cell homeostasis via PD1/PTEN/AKT signalling pathway in immune thrombocytopenia. 3060 80
